NCT06143839 2025-11-20
VYSION
Jazz Pharmaceuticals
Completed
Clinical Trials
10 trialsNCT04075747 2023-10-16
V-FAST
Jazz Pharmaceuticals
Phase 1 Completed
NCT04038437 2022-11-09
A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML
Jazz Pharmaceuticals
Phase 1 Completed
NCT05169307 2022-07-12
CPX-351 Real-World Effectiveness and Safety Study
Jazz Pharmaceuticals
Completed
NCT03555955 2021-07-22
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351
Jazz Pharmaceuticals
Phase 1 Completed
NCT01696084 2020-08-10
301
Jazz Pharmaceuticals
Phase 3 Completed
NCT02269579 2018-03-14
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
Phase 2 Withdrawn
NCT00788892 2018-01-12
Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
Jazz Pharmaceuticals
Phase 2 Completed
NCT02238925 2017-11-30
An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients
Jazz Pharmaceuticals
Phase 2 Completed
NCT00822094 2017-11-24
Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Jazz Pharmaceuticals
Phase 2 Completed